<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Leap Therapeutics, Inc.

    verified_userVerify Profile
    Companies » Health Care » Pharmaceuticals & Biotechnology » Pharmaceuticals

    About Leap Therapeutics, Inc.

    Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap's second clinical candidate, TRX518, is a humanized GITR agonist monoclonal antibody designed to enhance the immune system's anti-tumor response that is in advanced solid tumor studies. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Chris Mirabelli, Ph.D.
    • FOUNDED
      2011
    • EMPLOYEES
      20
    • SECTOR
      Pharmaceuticals & Biotechnology
    • SUBSECTOR
      Pharmaceuticals

    Company Tags

    No articles found.

    Vermillion, Inc.

    Vermillion, Inc.

    We are dedicated to the discovery, development, and commercialization of novel hig...

    We are dedicated to the discovery, development,...

    Filing Type:    PU
    Adamis Pharmaceuticals Corporation

    Adamis Pharmaceuticals Corporation

    Founded in 2006 and headquartered in San Diego, Adamis (ADMP) is a specialty bioph...

    Founded in 2006 and headquartered in San Diego,...

    Filing Type:    PU
    FreshMynd Inc.

    FreshMynd Inc.

    Freshmynd is developing a breakthrough ADHD supplement for kids backed by 20+ inde...

    Freshmynd is developing a breakthrough ADHD sup...

    Amount Raised:    $58,475.00
    Fundraising Status:    EC
    Filing Type:    CF
    Blueprint Medicines Corporation

    Blueprint Medicines Corporation

    Blueprint Medicines is a precision therapy company striving to improve human healt...

    Blueprint Medicines is a precision therapy comp...

    Filing Type:    PU
    Tonix Pharmaceuticals Holding Corp.

    Tonix Pharmaceuticals Holding Corp.

    Tonix is a clinical-stage biopharmaceutical company focused on discovering and dev...

    Tonix is a clinical-stage biopharmaceutical com...

    Filing Type:    PU
    ObsEva SA

    ObsEva SA

    Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company foc...

    Founded in November 2012, ObsEva is a clinical-...

    Filing Type:    PU
    Gamida Cell Ltd.

    Gamida Cell Ltd.

    Gamida Cell is a clinical-stage biopharmaceutical company committed to developing ...

    Gamida Cell is a clinical-stage biopharmaceutic...

    Filing Type:    PU
    Sierra Oncology, Inc.

    Sierra Oncology, Inc.

    Sierra Oncology is a clinical stage drug development company advancing targeted th...

    Sierra Oncology is a clinical stage drug develo...

    Filing Type:    PU
    Takeda Pharmaceutical Co., Ltd.

    Takeda Pharmaceutical Co., Ltd.

    Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-base...

    Takeda Pharmaceutical Company Limited (TSE:4502...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.